Bora Han

* Accomplished biopharmaceutical leader with 20 years experience in drug development, inclusive of nonclinical safety/toxicology, DMPK, pharmacology, regulatory affairs, and drug development operations * Expertise in multiple biopharmaceutical drug modalities: small molecues, monoclonal antibody, peptibody, fusion protein, bi-specific antibody, antibody drug conjugates (ADC), antibody oligo nucleotide conjugates, CAR-T, antibody-conjugated cellular therapy, and oligonucleotides. * In depth experience in oncology and immuno-oncology * In depth experience in therepeutic areas requiring special delivery route (i.e. ophthamology, inhaled respiratory therapy, and intra-articular administration for osteoarthritis) * Successfully created and headed nonclinical development function in start up and mid-size public biotech companies managing safety, DMPK, regulatory, and pharmacology * Held positions as a therapeutic area lead and functional area lead for a global large pharmaceutical company * Successfully led nonclinical development from concept to registration in multiple therapeutic areas and modalities—oncology, inflammation, ophthalmology, cardiovascular disorder, neurosciences, metabolic disorder, and pain * Successfully managed industry and academic collaborations * Served as the nonclinical expert in business development activities for in-licensing, out-licensing, and fund raising * Expertise in global regulatory strategy (nonclinical) with authoring and filing of numerous IND, NDA, and BLA * Portfolio leadership role for a prolific research unit within big biopharmaceutical company managing multiple high level scientists